Cargando…
Engineered mRNA and the Rise of Next-Generation Antibodies
Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs. The use of gene transfer methods for in vivo secretion of therapeutic anti...
Autores principales: | Sanz, Laura, Álvarez-Vallina, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544192/ https://www.ncbi.nlm.nih.gov/pubmed/34698057 http://dx.doi.org/10.3390/antib10040037 |
Ejemplares similares
-
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
por: Bogen, Jan P., et al.
Publicado: (2021) -
Rise of the RNA machines – self-amplification in mRNA vaccine design
por: Comes, Jerome D.G., et al.
Publicado: (2023) -
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023) -
Making the Next
Generation of Therapeutics: mRNA Meets
Synthetic Biology
por: Hınçer, Ahmet, et al.
Publicado: (2023) -
In vivo selection of tumor-specific antibodies
por: Sánchez-Martín, David, et al.
Publicado: (2013)